Revenue Showdown: Carlisle Companies Incorporated vs Rentokil Initial plc

Carlisle vs Rentokil: A Decade of Revenue Rivalry

__timestampCarlisle Companies IncorporatedRentokil Initial plc
Wednesday, January 1, 201432040000001740800000
Thursday, January 1, 201535432000001759000000
Friday, January 1, 201636754000002168100000
Sunday, January 1, 201740899000002412300000
Monday, January 1, 201844795000002472300000
Tuesday, January 1, 201948116000002676200000
Wednesday, January 1, 202039699000002789400000
Friday, January 1, 202148103000002953900000
Saturday, January 1, 202265919000003714000000
Sunday, January 1, 202345869000005375000000
Monday, January 1, 20245003600000
Loading chart...

Data in motion

Revenue Showdown: Carlisle vs Rentokil

In the competitive landscape of global business, Carlisle Companies Incorporated and Rentokil Initial plc have been vying for revenue supremacy over the past decade. From 2014 to 2023, Carlisle's revenue surged by approximately 43%, peaking in 2022 with a remarkable 6.6 billion USD. Meanwhile, Rentokil's revenue grew by an impressive 209%, reaching its zenith in 2023 with 5.4 billion USD.

A Decade of Growth

Carlisle's revenue trajectory showcases a steady climb, with a notable dip in 2020, likely due to global economic disruptions. However, the company rebounded strongly in 2022. Rentokil, on the other hand, demonstrated consistent growth, with a significant leap in 2023, surpassing Carlisle for the first time in this period.

The Future Outlook

As both companies continue to expand, investors and industry watchers will be keenly observing their strategies to maintain and enhance their market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
28 Jan 2025